Diasome Pharmaceuticlas, Inc.
Diasome is a biotech company focused on advancing liver-targeted metabolic therapies for diabetes, obesity, and metabolic diseases. Their innovative HDV™ platform enables precise delivery of drugs to the portal-hepatic region, aiming to improve efficacy and reduce side effects of treatments. Since 2012, they have been dedicated to translating scientific discovery into real-world patient impact, with a pipeline of therapies targeting insulin, serotonin, and incretins to address unmet needs in metabolic health.
Industries
Nr. of Employees
small (1-50)
Diasome Pharmaceuticlas, Inc.
Products
Liver-targeted rapid-acting mealtime insulin (injectable, Phase 2b)
A subcutaneous rapid-acting insulin candidate formulated on a hepatocyte-directed lipid nanoparticle designed to direct insulin to the liver to restore physiologic mealtime glucose regulation and reduce hypoglycemia risk.
Oral hepatocyte-directed serotonin replacement (preclinical)
An oral small-molecule/peptidic candidate delivered via hepatocyte-directed nanoparticles intended to restore portal-hepatic serotonin levels to improve hepatic insulin utilization and address insulin resistance.
Hepatocyte-directed GLP-1 incretin programs (preclinical)
Injectable and formulation-adapted incretin candidates (GLP-1 and GLP-1/GIP) using hepatocyte-directed nanoparticles to target the gut-liver-brain axis for metabolic endpoints.
Liver-targeted rapid-acting mealtime insulin (injectable, Phase 2b)
A subcutaneous rapid-acting insulin candidate formulated on a hepatocyte-directed lipid nanoparticle designed to direct insulin to the liver to restore physiologic mealtime glucose regulation and reduce hypoglycemia risk.
Oral hepatocyte-directed serotonin replacement (preclinical)
An oral small-molecule/peptidic candidate delivered via hepatocyte-directed nanoparticles intended to restore portal-hepatic serotonin levels to improve hepatic insulin utilization and address insulin resistance.
Hepatocyte-directed GLP-1 incretin programs (preclinical)
Injectable and formulation-adapted incretin candidates (GLP-1 and GLP-1/GIP) using hepatocyte-directed nanoparticles to target the gut-liver-brain axis for metabolic endpoints.
Expertise Areas
- Hepatocyte-targeted drug delivery
- Lipid nanoparticle formulation
- Oral and injectable formulation development
- Preclinical pharmacology and toxicology
Key Technologies
- Disc-shaped lipid nanoparticles
- Surface ligand-mediated hepatic targeting
- High-capacity payload loading
- Oral formulation technology